Arthroscopic Resection Arthroplasty of Carpometacarpal and/or Pantrapezial Osteoarthritis

Arthroscopic Resection Arthroplasty of Basal Joint Arthritis: Comparing Outcomes of Isolated Carpometacarpal to Pantrapezial Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02958137

Acronym

ARA:BJA-OA

Enrollment

125

Registered

2016-11-08

Start date

2004-01-31

Completion date

2011-12-31

Last updated

2016-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thumb Osteoarthritis

Brief summary

Compare outcomes of ARA for isolated CMC OA versus to simultaneous ARA of CMC plus STT

Detailed description

The purposes of this study were to report 1) long-term outcomes on a large series of patients that underwent arthroscopic resection arthroplasty (ARA) for thumb basal joint arthritis (BJA) and 2) to compare outcomes of ARA for isolated carpometacarpal osteoarthritis versus those undergoing simultaneous ARA of CMC plus the scaphotrapeziotrapezoid joint for pantrapezial disease. Please note, all patients treated by Dr. Cobb for CMC and/or STT OA received the same treatment regardless of whether or not they chose to participate in the study. Patients who chose to enroll in the study received the same treatment as those who did not only their data was analyzed. Data collection is the same for those who do not participate, only their data is not analyzed.

Interventions

PROCEDUREArthroscopic Resection Arthroplasty

Surgical removal of the arthritic joint(s) using a minimally invasive technique.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 83 Years

Healthy volunteers

Yes

Inclusion criteria

* Primary cases of ARA for thumb BJA with isolated CMC ARA or simultaneous ARA of the CMC and STT joints.

Exclusion criteria

* Exclusions included 19 cases that received interposition materials that since have been shown to produce unfavorable postoperative inflammatory responses, (Orthadapt Bioimplant, Pegasus Biologics, Irvine, CA and Artimplant Artelon CMC-I Spacer, Small Bone Innovations, LLC, New York, NY), 6 cases that had prior CMC surgery, and 27 cases that underwent concomitant surgeries that would potentially effect outcome.

Design outcomes

Primary

Measure	Time frame
Strength (pinch and grip)	Change from baseline to 2 year follow-up.

Secondary

Measure	Time frame	Description
Satisfaction with Perceived Surgical Outcome	Reported at 2 year postoperative follow-up	(0-5; 0 = not at all satisfied, 5 = completely satisfied)
Pain	Change from baseline to 2 year follow-up	numerical rating scale, (0-10; 0 = no pain, 10 = worst imaginable pain)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026